Trial Profile
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Sponsors Karyopharm Therapeutics
- 23 Dec 2020 Status changed from discontinued to completed.
- 06 Oct 2020 Results presented in a Karyopharm Therapeutics Media Release.
- 06 Oct 2020 According to a Karyopharm Therapeutics media release, data will be presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group (ISIRV-AVG) Virtual Conference on Therapeutics for COVID-19.